{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:49:47Z","timestamp":1792082987643,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Relapsed\/refractory (R\/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariably experience relapse. While newer therapies such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T cell) therapy are available, patient access and eligibility remain challenging. Here, we report the safety and efficacy of pirtobrutinib, a noncovalent (reversible) BTKi monotherapy in a R\/R FL cohort from the multicenter phase 1\/2 BRUIN study. Key end points included investigator-assessed overall response rate (ORR) per Lugano 2014 criteria, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Among 48 patients with FL, the median age was 64.5 years (range, 37.0-85.0). Patients had received a median of 3 (range, 1-12) prior lines of therapy. The ORR with pirtobrutinib was 52.1% (95% confidence interval [CI], 37.2-66.7), and median DoR was 10.2 months (95% CI, 3.7-25.7). Median PFS was 5.8 months (95% CI, 3.8-8.1), and median OS was not estimable, with a median follow-up of 35.2 months (interquartile range, 31.1-41.8). The estimated DoR, PFS, and OS rates at 24 months were 33.3% (95% CI, 15.9-51.9), 25.6% (95% CI, 13.9-39.1), and 75.1% (95% CI, 59.5-85.4), respectively. Pirtobrutinib was well tolerated, with 2 patients (4.2%) discontinuing treatment due to adverse events (AEs; 1 treatment-related) and 4 patients (8.3%) having dose reductions due to AEs (all treatment related). Pirtobrutinib showed promising efficacy and was well tolerated in this cohort of patients with heavily pretreated R\/R FL, warranting further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03740529.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014975","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T19:59:26Z","timestamp":1755892766000},"page":"5954-5964","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"2Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"3Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"5Division of Hematology Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9592-0851","authenticated-orcid":false,"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[{"name":"6Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"7Department of Hematology\/Oncology, Tokai University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7243","authenticated-orcid":false,"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-1331","authenticated-orcid":false,"given":"Bryone","family":"Kuss","sequence":"additional","affiliation":[{"name":"9Haematology and Molecular Genetics, Flinders Medical Centre and Flinders University, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-8829","authenticated-orcid":false,"given":"Kaname","family":"Miyashita","sequence":"additional","affiliation":[{"name":"10Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"11Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, University of California Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"13Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"14Florida Cancer Specialists, Sarasota, FL"},{"name":"15Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal A.","family":"Barve","sequence":"additional","affiliation":[{"name":"16Mary Crowley Cancer Research, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"17Nantes University School of Medicine and University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":false,"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"18New Drugs Development Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-9704","authenticated-orcid":false,"given":"Daigo","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Kochi Medical School Hospital, Nankoku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"22Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"23Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"24Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-8404","authenticated-orcid":false,"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"25Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"26Department of Haematology, St James's University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Sun","sequence":"additional","affiliation":[{"name":"27Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Bian","sequence":"additional","affiliation":[{"name":"27Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Balbas","sequence":"additional","affiliation":[{"name":"27Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Tsai","sequence":"additional","affiliation":[{"name":"27Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Abada","sequence":"additional","affiliation":[{"name":"27Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"28Linear Clinical Research, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"4","key":"2025120908562383100_bib1","first-page":"105","article-title":"Current trends in diagnosis and management of follicular lymphoma","volume":"12","author":"Gupta","year":"2022","journal-title":"Am J Blood Res"},{"issue":"1","key":"2025120908562383100_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","article-title":"Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies","volume":"14","author":"Hanel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025120908562383100_bib3","doi-asserted-by":"crossref","first-page":"1120358","DOI":"10.3389\/fonc.2023.1120358","article-title":"Treatment selection for patients with relapsed or refractory follicular lymphoma","volume":"13","author":"Skarbnik","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"2025120908562383100_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120908562383100_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2025120908562383100_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2025120908562383100_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2025120908562383100_bib8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120908562383100_bib9","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"2025120908562383100_bib10","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"key":"2025120908562383100_bib11","volume-title":"Brukinsa - opinion on variation to marketing authorisation","year":"2023"},{"key":"2025120908562383100_bib12","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma. Accessed 9 May 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma."},{"issue":"1","key":"2025120908562383100_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120908562383100_bib14","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"10277","key":"2025120908562383100_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2025120908562383100_bib16","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-Cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025120908562383100_bib17","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma. Accessed 9 May 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"2025120908562383100_bib18","volume-title":"Jaypirca EPAR (EMEA\/H\/C\/005863)","year":"2023"},{"key":"2025120908562383100_bib19","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. Accessed 9 May 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic."},{"key":"2025120908562383100_bib20","volume-title":"Jaypirca (pirtobrutinib). Package insert","year":"2025"},{"issue":"5","key":"2025120908562383100_bib21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120908562383100_bib22","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2022-159158","article-title":"Acalabrutinib plus rituximab with or without lenalidomide in patients with follicular lymphoma: a multipart, open-label, phase 1b trial","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"issue":"33","key":"2025120908562383100_bib23","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025120908562383100_bib24","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1182\/blood-2019-128677","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"134","author":"Amitai","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2025120908562383100_bib25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2025120908562383100_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"issue":"24","key":"2025120908562383100_bib27","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"issue":"14","key":"2025120908562383100_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025120908562383100_bib30","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025120908562383100_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2024-194627","article-title":"5-year follow-up analysis from ZUMA-5: a phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"144","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2025120908562383100_bib32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025120908562383100_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2025120908562383100_bib34","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025120908562383100_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025120908562383100_bib38","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-20-3741","article-title":"Follicular lymphoma\u2013associated BTK mutations are inactivating resulting in augmented AKT activation","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025120908562383100_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cam4.4422","article-title":"Identification of a genetic signature enriching for response to ibrutinib in relapsed\/refractory follicular lymphoma in the DAWN phase 2 trial","volume":"11","author":"Balasubramanian","year":"2022","journal-title":"Cancer Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5954\/2423302\/blooda_adv-2024-014975-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5954\/2423302\/blooda_adv-2024-014975-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:56:33Z","timestamp":1765288593000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/5954\/546861\/Pirtobrutinib-a-highly-selective-noncovalent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":36,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014975","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,11,26]]}}}